Tech Company Financing Transactions
Mestag Therapeutics Funding Round
On 3/17/2026, Mestag Therapeutics raised $40 million in financing from Forbion Capital Partners, GV and Johnson & Johnson Innovation.
Transaction Overview
Company Name
Announced On
3/17/2026
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The financing will support the Phase 1 STARLYS clinical study, which is anticipated to start in cancer patients in mid-2026.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Science Village, Chesterford Research Park, Little Chesterfo 15
Cambridge, CB10 1XL
UK
Cambridge, CB10 1XL
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Mestag is an immunotherapy company harnessing new insights into fibroblast-immune cell interactions to develop innovative treatments for cancer and inflammatory diseases. Through our unique understanding of fibroblast biology, we are advancing a pipeline of first-in-class tailored antibody programs and exploring innovative targets for new treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Susan Hill
Chief Scientific Officer
Ray Jupp
VP - Bus. Development
Robert de Jonge
VP - Finance
Eilidh Goodwin
Browse more venture capital transactions:
Prev: 3/17/2026: Surf Therapeutics venture capital transaction
Next: 3/17/2026: Tenkara venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs